ABBV · News · 20260903N

Guidance / Outlook

AbbVie Inc. · 2026-09-03 · Importance 36 · Surprise 24

AbbVie reaffirmed its full-year 2026 adjusted diluted EPS guidance range of $13.87 to $14.07. It also reaffirmed third-quarter 2026 adjusted diluted EPS guidance of $3.84 to $3.88. The reaffirmation followed completion of the Apogee acquisition, despite reported expected near-term EPS dilution from the transaction. Management’s outlook relies on continued contributions from Skyrizi, Rinvoq and neuroscience products to offset Humira erosion.

Key facts

• AbbVie reaffirmed its 2026 full-year adjusted diluted EPS guidance range of $13.87 - $14.07. source
• AbbVie reaffirmed its previously issued third-quarter adjusted diluted EPS guidance range of $3.84 - $3.88. source
• AbbVie will participate in the Morgan Stanley 24th Annual Global Healthcare Conference on Tuesday, September 15, 2026. source